tradingkey.logo

Gain Therapeutics Inc <GANX.OQ> expected to post a loss of 18 cents a share - Earnings Preview

ReutersMay 9, 2025 3:23 PM
  • Gain Therapeutics Inc GANX.OQ GANX.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • The Bethesda Maryland-based company is expected to report revenue of $25 thousand, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Gain Therapeutics Inc is for a loss of 18 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00​, above​ its last closing price of $2.03. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.17

-0.18

-0.11

Beat

40

Sep. 30 2024

-0.22

-0.21

-0.17

Beat

20.9

Jun. 30 2024

-0.19

-0.20

-0.42

Missed

-110​

Mar. 31 2024

-0.29

-0.29

-0.22

Beat

24.8

​​Dec. 31 2023

-0.30

-0.32

-0.36

Missed

-11.6

Sep. 30 2023

-0.45

-0.45

-0.37

Beat

17​

Jun. 30 2023

-0.32

-0.31

-0.62

Missed

-101.6

Mar. 31 2023

-0.40

-0.39

-0.43

Missed

-9.3

This summary was machine generated May 9 at 15:23 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI